Strategy for peptide quantification using LC-MS in regulated bioanalysis: case study with a glucose-responsive insulin

Bioanalysis. 2018 Aug 1;10(15):1207-1220. doi: 10.4155/bio-2018-0089. Epub 2018 Jul 31.

Abstract

Advances in technology have led to a shift for peptide quantification from traditional ligand-binding assays to LC-MS/MS-based analysis, which presents challenges, in other assay sensitivity, specificity and ruggedness, in addition to lacking of regulatory guidance, especially for the hybrid assay format. Methodology & results: This report communicates a strategy that has been employed in our laboratories for method development and assay validation, and exemplified in a case study of MK-2640, a glucose-responsive insulin, in multiple matrices. Intact MK-2640 was monitored, while immunoaffinity purification and SPE were used to support the rat/dog GLP and clinical studies, respectively. The rationale and considerations behind our approach, as well as the acceptance criteria applied to the assay validation are discussed.

Keywords: GRI; glucose-responsive insulin; hybrid assay; peptide quantification.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Chromatography, Affinity
  • Chromatography, High Pressure Liquid*
  • Dogs
  • Half-Life
  • Humans
  • Insulin / analogs & derivatives*
  • Insulin / analysis
  • Insulin / chemistry
  • Insulin / pharmacology
  • Insulin, Long-Acting / chemistry
  • Insulin, Short-Acting / chemistry
  • Insulins / chemistry
  • Insulins / immunology
  • Limit of Detection
  • Peptides / blood*
  • Peptides / isolation & purification
  • Peptides / pharmacokinetics
  • Rats
  • Reproducibility of Results
  • Solid Phase Extraction
  • Tandem Mass Spectrometry*

Substances

  • Antibodies, Monoclonal
  • Insulin
  • Insulin, Long-Acting
  • Insulin, Short-Acting
  • Insulins
  • MK-2640
  • Peptides